Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can estrogen rewire how the brain learns fear?

NCT ID NCT07737613

Knowledge-focused Sponsor: University of Arizona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study explores whether estrogen influences how the brain processes fear, focusing on postmenopausal women who experience natural declines in the hormone. Participants will take an estradiol tablet and undergo brain scans while viewing shapes that sometimes predict a mild electric shock. The goal is to understand how hormones and cognition together affect fear learning and anxiety risk later in life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
estradiol (a form of estrogen) given as an oral tablet
What this could lead to
If it works, this could point toward ways to reduce anxiety and PTSD risk in older women by understanding how estrogen influences fear processing.
What could go wrong
This is a very early, small study focused on brain activity, not on treating any condition. Results may not lead to practical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * post-menopausal * normal or corrected-to-normal vision * English speaking * stable medication use (no changes in the past three months) Exclusion Criteria: * use of hormone therapy containing synthetic estrogen * MRI contraindications (e.g., irremovable ferrous metal in body, claustrophobia) * history of neurological disorder (including mild cognitive impairment) or moderate to severe traumatic brain injury * use of antipsychotic, opiate, or mood stabilizer (i.e., lithium) medication * history of blood clots/deep vein thrombosis, prior stroke or TIA, uncontrolled hypertension * history of migraine with aura * severe liver disease * history of breast, endometrial, or ovarian cancer * smoking \>10 cigarettes/day

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline in older adults are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive decline in older adults Post-menopausal women PTSD and trauma-related symptoms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.